This module overviews the STEP clinical trial programme for once-weekly semaglutide 2.4 mg for the management of body weight in people with overweight and obesity. The module covers STEP trials 1 to 4 and includes the objectives, patient populations, and top-line results for each of the 4 trials. Results from these trials include the effect of semaglutide on body weight as well as the effect on cardiometabolic risk factors.
At the end of this module, you will understand how semaglutide 2.4 mg reduces body weight in people with overweight and obesity and be familiar with the design and overall results for body weight reduction and cardiometabolic risk factors for STEP trials 1 to 4.